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E-mail: l.dewindt@maastrichtuniversity.nlHeart failure is preceded by ventricular remodeling, changes in
left ventricular mass, and myocardial volume after alterations
in loading conditions. Concentric hypertrophy arises after pres-
sure overload, involves wall thickening, and forms a substrate for
diastolic dysfunction. Eccentric hypertrophy develops in volume
overload conditions and leads wall thinning, chamber dilation,
and reduced ejection fraction. The molecular events underlying
these distinct forms of cardiac remodeling are poorly under-
stood. Here, we demonstrate that miR-148a expression changes
dynamically in distinct subtypes of heart failure: while it is
elevated inconcentrichypertrophy, itdecreased indilated cardio-
myopathy. In line, antagomir-mediated silencing of miR-148a
caused wall thinning, chamber dilation, increased left ventricle
volume, and reduced ejection fraction. Additionally, adeno-asso-
ciated viral delivery ofmiR-148a protected themouse heart from
pressure-overload-induced systolic dysfunction by preventing
the transition of concentric hypertrophic remodeling toward
dilation. Mechanistically, miR-148a targets the cytokine co-re-
ceptor glycoprotein 130 (gp130) and connects cardiomyocyte
responsiveness to extracellular cytokines by modulating the
Stat3 signaling.
These findings show the ability ofmiR-148a to prevent the tran-
sition of pressure-overload induced concentric hypertrophic
remodeling toward eccentric hypertrophy and dilated cardio-
myopathy and provide evidence for the existence of separate
molecular programs inducing distinct forms of myocardial re-
modeling.
INTRODUCTION
Heart failure is a major cause of morbidity and death with little recent
progress to reduce its high mortality. This disease is preceded by
ventricular remodeling, changes in left ventricular mass, and volume
of the myocardium in response to alterations in loading conditions,584 Molecular Therapy Vol. 27 No 3 March 2019 ª 2018 The Author(s)
This is an open access article under the CC BY-NC-ND license (httpwith two distinct outcomes. Concentric hypertrophy results from car-
diac growth and wall thickening, which arises from pressure overload
situations on the heart, as observed in patients with chronic hyperten-
sion, aortic valve stenosis, or inherited forms of hypertrophic cardio-
myopathy, and often yields a substrate for left ventricular diastolic
dysfunction.1,2 Contrary, eccentric hypertrophy often develops under
conditions of volume overload of the myocardium, with mitral and
aortic regurgitation or familial dilated cardiomyopathy as clinical cor-
relates, resulting in pronounced systolic dysfunction and a concomi-
tant decrease in ejection fraction.2 Pathological forms of concentric
hypertrophy in certain hypertensive or aortic stenosis patients in
time may gradually lead to eccentric remodeling of the heart and
worsening prognosis.3 Despite this spectrum of clinically relevant
cardiac remodeling phenotypes, the molecular events that underlie
these distinct forms of cardiac hypertrophy still remain poorly under-
stood.4 Accordingly, the stimulatory circulatory agonists, membrane-
bound receptors, and intracellular signaling cascades that connect
biomechanical forces and the activation of myocardial stress path-
ways are central to understanding the initiation and progression to
concentric versus eccentric hypertrophy.
Cardiotrophin-1 (CT-1), a member of the interleukin-6 (IL-6)
cytokine superfamily, exerts its pleiotropic functions using a gp130
homodimer or gp130-leukemia inhibitory factor receptor-b (LIFRb)
heterodimer, induces eccentric hypertrophy in cultured primary.
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. miR-148a Shows Dynamic Expression Patterns in Distinct Forms of Heart Failure
(A) Schematic representation of the genomic localization and precursor sequence of mmu-miR-148a located on the opposite strand on chromosome 6 in the mouse
genome. The maturemiR-148a-3p strand is conserved among several species. (B) Northern blot analysis ofmiR-148a-3p expression in diverse mouse organs. (C) RT-PCR
(legend continued on next page
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Molecular Therapycardiomyocytes in vitro5–7 and exerts cardioprotective proliferative
and survival effects in cultured embryonic, neonatal, or adult cardio-
myocytes.8–11 In vivo, CT-1 treatment induces left ventricular dilation
in rats.12 In humans, increased CT-1 serum levels are observed in
patients with unstable angina,13 acute myocardial infarction,14 hyper-
tension, valvular diseases, or heart failure,15 correlated with the degree
of left ventricular systolic dysfunction16,17 and left ventricular mass
index in patients with dilated cardiomyopathy.18,19
Cytokines of the IL-6 superfamily couple to gp130 receptors and
confer a level of cellular protection against cell death mechanisms
in a variety of cardiac stress conditions, and genetic deletion strategies
of gp130 or downstream signaling components render widespread
cell death in the myocardium in response to biomechanical
stress.20–22 On the other hand, unrestrained activation of cytokine-
gp130 signaling transmits prohypertrophic cues that facilitate the
transition to eccentric hypertrophy and systolic dysfunction,23 sug-
gesting that the expression of gp130 is determinant in the balance
between cellular survival pathways versus maladaptive hypertrophic
remodeling in the myocardium.
Here, we demonstrate that cardiac expression of miR-148a alters
dynamically in distinct subtypes of human and mouse forms of heart
failure. In human and mouse forms of concentric hypertrophy, miR-
148a expression is elevated, while forms of dilated cardiomyopathy
are accompanied by profoundly decreased miR-148a myocardial
expression. In the heart, miR-148a targets gp130 and determines
the extracellular cytokines responsiveness and cardiac signaling
strength of canonical STAT3 hypertrophic signaling by altering the
abundance of gp130. These findings provide evidence that myocardial
miR-148a functions to prevent the transition of pressure-overload
induced concentric hypertrophic remodeling toward eccentric hyper-
trophy and are proof of the existence of separable molecular cues that
provoke distinct forms of hypertrophy in the early steps toward
end-stage heart failure.
RESULTS
miR-148a Is Dynamically Expressed in Heart Failure Subtypes
From previous microRNA profiling studies in human cardiac biopsies
and mouse cardiac disease models, we observed that miR-148a-3p
displayed opposite expression patterns depending on the type of heart
disease studied.24 miR-148a is an intergenic microRNA, located on
chromosome 6 or 7 in the murine and human genome, respectively,
and distantly flanked by lncRNA genes (Figure 1A). The major
mature miR-148a form in the heart is miR-148a-3p, which is
fully conserved from the mouse to human genome, indicating ananalysis ofmiR-148a-3p expression in diverse mouse organs. (D) RT-PCR analysis ofm
from adult mouse hearts. (E) RT-PCR analysis of miR-148a-3p expression in human
cardiomyopathy, or human left ventricular myocardium with dilated cardiomyopathy. (F
knockout mice, the gene encoding muscle LIM protein (MLP). (G) RT-PCR analysis of
Myh6-CnA transgenic mice. Data are means ± SEM. One-way ANOVA with Bonferroni’s
groups. n, number of hearts; NF, non-failing; DCM, dilated cardiomyopathy; HCM, hyp
myosin heavy chain; CnA, calcineurin. *p < 0.05 versus corresponding control group.
586 Molecular Therapy Vol. 27 No 3 March 2019evolutionary pressure to resist variations in this microRNA gene (Fig-
ure 1A). Northern blotting revealed that miR-148a is broadly
expressed in various tissues, with a relatively high expression in
kidney, spleen, and lung, to a lesser extent in liver and heart, and
with traces of expression in brain, muscle, and fat tissue (Figure 1B).
In the heart, miR-148a is most abundantly expressed in cardiomyo-
cytes and fibroblasts (Figure 1D). Most remarkable, miR-148a
displayed an opposite direction of differential expression in human
cardiac biopsies of end-stage heart failure obtained upon heart trans-
plantation, with a pronounced decrease of miR-148a in left ventricu-
lar biopsies of dilated cardiomyopathy compared to healthy controls
(Figure 1E), compared to an increased expression of miR-148a in the
left ventricular myocardium of patients with hypertrophic cardiomy-
opathy compared to the respective healthy controls (Figure 1E). Next,
we compared cardiac miR-148a expression differences in mouse
models of dilated or hypertrophic cardiac remodeling. Cysteine and
glycine-rich protein 3 (Csrp3), also known as muscle LIM protein,
is a Z disc protein involved in cardiac mechanical stretch sensing
and required for proper cardiac geometry, energy metabolism, and
function. Mice homozygous null forCsrp3 develop early-onset dilated
cardiomyopathy and have been extensively used to study the patho-
physiology of this subtype of heart failure. Csrp3 null mice displayed
a very strong reduction of miR-148a in left ventricular tissue (Fig-
ure 1F). In contrast, mice harboring a constitutively activated mutant
of calcineurin A (CnA) under control of the myosin heavy-chain
promoter (Myh6-CnA) develop severe hypertrophic concentric
remodeling soon after birth. Hearts from young Myh6-CnA mice re-
vealed an increase in miR-148a expression (Figure 1G). Taken
together, cardiac miR-148a expression is increased in human and
mouse forms of concentric hypertrophic cardiac remodeling and
decreased in human and mouse forms of eccentric remodeling or
dilated cardiomyopathy.
miR-148a Targets Cardiac Glycoprotein 130
MicroRNAs exert their action by regulating gene expression at the
post-transcriptional level by imperfect base pairing with protein-
coding transcripts. Hence, to understand the mechanistic role of
miR-148a in cardiac remodeling, we first performed a bioinformatic
analysis aimed at identifying miR-148a binding sites in cardiac ex-
pressed protein-coding transcripts. We identified an enrichment of
three putative miR-148a seed regions in IL-6 signal transducer
(Il6st), better known as glycoprotein 130 (gp130), and among them,
the more proximal miR-148a binding site in the 2.5 kb gp130 30
UTR demonstrated a perfect match for the miR-148a heptametrical
seed sequence and showed complete evolutionary conservation (Fig-
ure 2A; Figures S2A and S2B). The gp130 co-receptor couples theiR-148a-3p expression in isolated cardiomyocytes, fibroblasts, and endothelial cells
non-failing (control) hearts, human left ventricular myocardium with hypertrophic
) RT-PCR analysis of miR-148a-3p expression in hearts from wild-type and Csrp3
miR-148a-3p expression in hearts from 3-week-old non-transgenic littermates and
multiple-comparison test or Student’s paired two-tailed t test was used to compare
ertrophic cardiomyopathy; Csrp3, cysteine and glycine-rich protein 3; Myh6, alpha
Figure 2. miR-148a Targets gp130 and Differentially Regulates gp130 Downstream Signaling in Concentric and Eccentric Cardiac Remodeling
(A) Location and evolutionary conservation of the mmu-miR-148a seed region on gp130 30 UTR (Ensemble: ENSMUST00000183663.7). (B) Schematic representation of
luciferase reporter constructs. (C) Activity assay of luciferase reporter constructs in Cos7 cells. (D) Western blot for endogenous gp130 in neonatal rat cardiomyocytes when
transfected with scrambled control antimir (scr.anti-miR), antimir-148a (anti-miR-148a), or precursor for miR-148a (pre-miR-148a) and quantification of tubulin-corrected
gp130 western blot signals. (E) Design of the study: 2-month-old mice were subjected to sham or TAC surgery for 2, 4, 6, or 8 weeks. Mice were subjected to echocar-
diographic evaluation and hearts harvested at indicated time points. (F) RT-PCR analysis of miR-148a-3p expression at indicated time points. (G–I) Echocardiographically
determined LV mass divided by BW (G), EF (H), or LVIDs (I), respectively. (J) Western blot analysis of myocardial CT-1 expression and quantification at indicated time points.
(K) Western blot analysis of myocardial gp130 expression and quantification at indicated time points. (L) Western blot analysis of myocardial phosphorylated and
(legend continued on next page)
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Molecular Therapyresponsiveness of the heart to cytokines from the IL-6 family,
including IL-6, LIF, oncostatin M (OSM), or CT-1, and intracellular
MAPK, phosphatidylinositol 3-kinase (PI3K), or JAK/STAT
signaling by homodimerization or heterodimerization with LIF re-
ceptors at the cell surface.25
To more directly establish the regulation of gp130 bymiR-148a in the
myocardium, we generated series of luciferase reporters harboring
either the complete or truncated forms of the gp130 30 UTR, including
a reporter with site-directed mutagenesis of key nucleotides in the
miR-148a binding site (Figure 2B). Transient transfection of synthetic
precursor miR-148a in cultured Cos7 cells decreased gp130 30 UTR
reporter activity when either the intact 2.5 kb 30 UTR or a distal
truncation was coupled to luciferase compared to co-transfection
with scrambled precursor molecules (Figure 2C). In contrast, a
proximal truncation of the gp130 30 UTR, harboring two putative
miR-148a binding sites, as well as a site-directed mutant of the com-
plete gp130 30 UTR, remained unresponsive to synthetic precursor
miR-148a molecules (Figure 2C). In line, endogenous gp130 protein
expression in primary cardiomyocytes was derepressed by transfec-
tion of miR-148a antimir molecules, while pretreatment with
miR-148a precursor molecules provoked significant downregulation
of endogenous gp130 at the protein level (Figure 2D).
miR-148a Dynamically Influences gp130 Downstream Signaling
miR-148a expression was found increased in forms of concentric
hypertrophic cardiac remodeling, while its expression was downregu-
lated in forms of eccentric cardiac remodeling (Figures 1E–1G). To
mimic this dynamic expression pattern in vivo and study the effects
of differential miR-148a expression on gp130 expression levels and
downstream signaling events in the intact heart, we subjected cohorts
of mice to pressure overload by transverse aortic constriction (TAC)
surgery, serially assessed cardiac geometry and function and sacri-
ficed mice at 0 weeks (sham) or 2, 4, 6, or 8 weeks after TAC to mea-
sure cardiacmiR-148a expression and evaluate the activation status of
signaling cascades (Figures 2E–2L). In line with our previous observa-
tions,24,26,27 concentric hypertrophic remodeling with sustained
systolic function was evident in mice in the first 4 weeks following
TAC surgery, which gradually transitioned to eccentric remodeling
and loss of systolic contractile performance. First, miR-148a expres-
sion gradually increased up to 10-fold in pressure-overloaded hearts
following 2 or 4 weeks of TAC compared to hearts from sham-oper-
ated mice (Figure 2F). In this time period, pressure-overloaded hearts
increased in heart mass but still displayed sustained systolic function
and showed no signs of left ventricular dilation, consistent with
concentric hypertrophic remodeling (Figures 2G–2I). More pro-
longed periods of pressure overload induced a subsequent steep
reduction of cardiac miR-148a expression, resulting in a significantly
lowermiR-148a expression at 8 weeks of pressure overload comparedunphosphorylated forms of STAT3 and quantification at indicated time points. Data a
comparison test was used to compare groups. n, number of transfection experiments
constriction; LV mass divided by BW, left ventricular mass to body weight ratio; EF, e
corresponding control group.
588 Molecular Therapy Vol. 27 No 3 March 2019to sham-operated mice (Figure 2F). Interestingly, at 6 and 8 weeks
following TAC, when miR-148a expression steeply reduced, left
ventricular mass was clearly increased compared to 2 and 4 weeks
after TAC. Additionally, at 6 and 8 weeks following TAC surgery, sys-
tolic function was drastically reduced and hearts displayed substantial
left ventricular dilation concordant with further eccentric cardiac
remodeling compared to 2 and 4 weeks after TAC (Figures 2G–2I).
Conclusively, in sustained pressure overload, concentric cardiac re-
modeling in early phases correlated with high miR-148a expression,
while eccentric cardiac remodeling in later phases correlated with
low expression of miR-148a.
Using this model of transient elevation and reduction of miR-148a
accompanied with a phenotypic switch from concentric to eccentric
cardiac remodeling, we assessed expression and activation status of
the CT-1/gp130 co-receptor axis. This CT-1/gp130 co-receptor axis
has been reported to result in ERK1/2 or ERK5 MAPK, PI3K/Akt,
or JAK/STAT3 downstream signaling activation in the heart.11 Our
data show that cardiac CT-1 levels gradually increase in time with
the pressure overload stimulus until 6 weeks after TAC, after which
this increase ceased (Figure 2J). Interestingly, the expression of the
direct miR-148a target gene gp130 was reduced by 50% at week
4 after TAC, a time point that coincides with the highest induction
of cardiac miR-148a expression (Figure 2K). We also determined
the expression of LIF, the LIFR itself, IL-6, ciliary neurotrophic factor
(CNTF), and oncostatin M as possible ligands that could all signal
through the gp130 co-receptor. No changes in LIF receptor expres-
sion were evident during this time period, the expression changes
in LIF or OSM remained unchanged or only demonstrated a transient
increase at 2 weeks of TAC surgery as was the case for CNTF or IL-6
(Figures S1A and S1E–S1H). These observations lend support to a
specificity of the interaction between miR-148a and CT-1/gp130 co-
receptor axis. A reduction in gp130 expression would be expected
to result in ramifications in the activation status of downstream
ERK1/2 or ER5 MAPK, PI3K/Akt, or JAK/STAT3 signaling. Indeed,
in this model of sustained pressure overloading, a reduction in both
phosphorylated STAT3 (Figure 2L) and phosphorylated Akt (Fig-
ure S1B), but not total STAT3 or Akt expression, was evident at early
time points after TAC, which coincided with the highest induction of
cardiacmiR-148a expression and lowest expression of gp130 (Figures
2F and 2K). No changes in ERK5 or ERK1/2 activation were evident at
the time points analyzed (Figures S1C and S1D).
CT-1-mediated gp130 activation and signaling is well known to
induce eccentric hypertrophic remodeling and chamber dilatation.
Despite clinical and experimental evidence that CT-1 levels are
elevated in plasma and myocardium of patients with heart failure,
direct evidence that CT-1 is sufficient to promote aspects of cardiac
disease in vivo is conspicuously lacking in literature. To addressre means ± SEM. One-way ANOVA with Bonferroni’s or Newman-Keul’s multiple-
(C), number of transfected wells (D), number of mice (F–L). TAC, transverse aortic
jection fraction; LVIDs, left ventricular internal diameter in systole. *p < 0.05 versus
Figure 3. miR-148a Silencing Promotes Spontaneous Eccentric Hypertrophic Remodeling and Dilated Cardiomyopathy In Vivo
(A) Design of the study. Two-month-old wild-type mice were injected with a control antagomir targeting C. elegans miR-39 (antagomir-Cel-39) or antagomir against
mmu-miR-148a-3p and subjected to sham or TAC surgery. Cardiac geometry and function was determined by serial Doppler echocardiography at 3 weeks and 6 weeks
after surgery. (B) RT-PCR analysis ofmiR-148a-3p and unrelated let-7b expression in hearts from mice receiving control antagomir (antagomir-Cel-39) or antagomir against
(legend continued on next page)
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by attenuating gp130 responsiveness to CT-1, we compared cardiac
phenotypes of mice that were either left untreated, infused with
20 mg/kg/day of CT-1,12 or infused with 60 mg/kg/day isoprotero-
nol28 for 2 weeks (Figure S2C). Our data demonstrate that isoproter-
enol exposure produced a classical cardiac hypertrophic response
accompanied by increased cardiac mass and wall thickening, intersti-
tial fibrosis, and reduced ejection fraction (Figures S2D–S2G).
Remarkably, sustained CT-1 exposure produced typical features of
eccentric remodeling with mild cardiac enlargement, wall thinning,
and severe systolic dysfunction (Figures S2D–S2G). Having estab-
lished that CT-1 is a direct stimulator of eccentric cardiac remodeling
in vivo, we observed that primary cardiomyocytes responded to CT-1
with a mild hypertrophic response in vitro, which was clearly attenu-
ated by transfection of synthetic precursor miR-148a molecules
(Figures S2H and S2I). Taken together, these data provide evidence
for miR-148a-based regulation of gp130 expression in the adult heart,
influencing the responsiveness of the heart to the pro-hypertrophic
agonist CT-1.
miR-148a Silencing Provokes Dilated Cardiac Remodeling
To further address the involvement of miR-148a in cardiac remodel-
ing, we made use of an antagomir to specifically silence endogenous
miR-148a expression in vivo, a situation that mimics cardiac miR-
148a reduction as observed in hearts from human and mouse models
of dilated cardiomyopathy (Figures 1E and 1F). To this end, we
designed chemically modified antisense oligonucleotides to target
either Caenorhabditis elegans miR-39-5p as control antagomir (anta-
gomir-ctrl or antagomir-Cel-39) or mmu-miR-148a-3p (antagomir-
148a). Antagomirs (80 mg/kg/day) were delivered by intraperitoneal
(i.p.) injection on 3 consecutive days to wild-type mice randomized to
receive sham or TAC surgery for 6 weeks (Figure 3A). Cardiac
miR-148a expression was efficiently silenced (Figure 3B).
Remarkably, antagomir-148a treatment sufficed to provoke a mild
form of eccentric remodeling with systolic dysfunction in sham-oper-
ated mice at 6 weeks after sham operation (Figure 3C). As expected,
upon TAC surgery the left ventricular weight (LV)-to-body weight
(BW) ratio increased (Figure 3D). As expected, TAC surgery in
mice treated with a control antagomir provoked transient hypertro-
phic remodeling with relatively well-preserved cardiac function at
3 weeks (Table S1). Six weeks of TAC surgery in mice treated with
a control antagomir or antagomir-148a resulted in severe myocyte
disarray, interstitial fibrosis, systolic and diastolic dysfunction, leftmiR-148a. (C) Representative images of whole hearts (top panel), H&E-stained sections
panel), Sirius-red-stained sections (fourth panel), andWGA-stained (fifth panel) histologic
echocardiography in antagomir control and antagomir-148a-treatedmice after sham or T
area in control and antagomir-148a-treated mice after sham or TAC surgery. (J) RT-PC
Nppb, Acta1, and Myh7 in hearts from control antagomir or antagomir-148a-treated m
myocardial gp130 (L) or phosphorylated and unphosphorylated forms of STAT3 (M) in he
control antagomir (antagomir-Cel-39). Data aremeans ±SEM. One-way ANOVAwith Bo
n, number of hearts; TAC, transverse aortic constriction; WGA, wheat germ agglutinin
posterior wall end systole; LVIDs, left ventricular internal diameter in systole; EF, ejection
alpha skeletal actin; Myh7, beta myosin heavy chain. *p < 0.05 versus corresponding c
590 Molecular Therapy Vol. 27 No 3 March 2019ventricular dilation, increased heart weight, as well as an induction
of a “fetal” gene program with a tendency of more severe phenotypes
in antagomir-148a-treated mice (Figures 3C–3J; Table S2). Next, we
analyzed protein levels of gp130 and p-STAT3 by western blotting.
The data demonstrate that silencing miR-148a in sham-operated
mice substantially derepressed (induced) its downstream target
gp130 (Figure 3K). As a result, the phosphorylated (activated) form
of STAT3 was increased when gp130 was increased in expression
(Figure 3K). Total expression levels of STAT3 remained unchanged,
indicating activation of STAT3 downstream of gp130 signaling in the
heart (Figures 3L and 3M). This result further supports our conclu-
sion that endogenous miR-148a expression levels directly target
gp130, subsequently resulting in activation of STAT3 signaling in
the heart. Taken together, these data demonstrate that miR-148a
silencing in vivo evokes mild cardiac dilation with derepression of
gp130 under baseline conditions and mildly exacerbated pressure
overload-induced cardiac remodeling and dysfunction.
miR-148a Overexpression Suppresses Pressure Overload-
Induced Cardiac Dilation
Next, we mimicked the increased expression ofmiR-148a as observed
in conditions of concentric cardiac remodeling in human and mouse
hypertrophic cardiomyopathy (Figures 1D and 1F). To this end, we
made use of the high cardiac tropism and prolonged expression of
viral vectors based on adeno-associated vector serotype9 (AAV9)
upon systemic delivery. AAV9 vectors expressing either mmu-miR-
148a (AAV9-148a) or an empty control vector (AAV9-MCS) were
administered intravenously (i.v.) by injection into the internal jugular
vein of adult mice (Figure 4A). The hearts of AAV9-148a-injected
animals displayed an induction of miR-148a of about 2-fold over
control (Figure 4B) and appeared morphologically normal, with no
signs of cardiomyocyte hypertrophy, changes in collagen content,
or induction of a fetal gene program apart from a mild induction of
Nppa (Figures 4C–4J), indicating that increasedmiR-148a expression
alone is not an active driver of cardiac hypertrophy or remodeling
in vivo in the absence of additional stimuli.
To analyze miR-148a cardiac function under pressure-overload con-
ditions, AAV9-148a and AAV9-MCS-treated animals were random-
ized to receive sham or TAC surgery. Six weeks of TAC surgery in
AAV9-MCS mice resulted in increased LV, severe myocyte disarray,
interstitial fibrosis, increased cardiomyocyte size, systolic and dia-
stolic dysfunction, left ventricular dilation, as well as an induction
of the classical “fetal” gene program (Figures 4C–4J; Tables S3 andof four-chamber view (second panel), high-magnification H&E-stained sections (third
al sections. (D) Measurement of LVmass/BW ratio, (E) LVPWs, (F) LVIDs, or (G) EF by
AC surgery. Measurements of (H) fibrotic area (Sirius red staining) and (I) cell-surface
R analysis of transcript abundance of the hypertrophic stress marker genes Nppa,
ice after sham or TAC surgery. (K–M) Western blot analysis (K) and quantification of
arts frommice subjected to sham or TAC surgery and receiving antagomir-148a or a
nferroni’s or Newman-Keuls multiple-comparison test was used to compare groups.
; LV mass/BW, left ventricular mass to body weight ratio; LVPWs, left ventricular
fraction; Nppa, natriuretic peptide type A; Nppb, natriuretic peptide type B; Acta1,
ontrol group.
(legend on next page)
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Molecular TherapyS4). In addition, cardiomyocyte apoptosis was increased in TAC sam-
ples compared to both sham groups (Figure S4). Strikingly, cardiac
histopathology, cardiomyocyte hypertrophy, and systolic function
were clearly attenuated in AAV9-148a-injected mice after 6 weeks
of TAC surgery (Figures 4C–4J; Table S4). A more pronounced in-
duction of transcripts encoding Nppa, Acta1, and Myh7 as part of
the “fetal” gene program was observed in hearts from AAV9-148a-in-
jected mice receiving TAC surgery compared to AAV9-MCS-injected
mice that received TAC surgery (Figure 4J). Importantly, the extent of
cardiomyocyte apoptosis was similar between the two groups
receiving TAC surgery (Figure S4).
We also performed western blotting in hearts from the four experi-
mental groups. We probed the membranes with antibodies specific
for gp130 or its immediate downstream signal transducer STAT3 to
assess phospho-STAT3 and total STAT3 levels. The data demonstrate
that overexpression ofmiR-148a substantially reduced the expression
of its downstream target gp130 (Figures 4K–4M). As a result, the
phosphorylated (activated) form of STAT3 was decreased when
gp130 was reduced in expression. Total expression levels of STAT3
remained unchanged, indicating reduced activation status of
STAT3 downstream of gp130 signaling in the heart. This result
further supports our conclusion that endogenous miR-148a controls
gp130 expression levels, subsequently resulting in differential activa-
tion status of STAT3 in the heart. Conclusively, these data demon-
strate that elevation of cardiac miR-148a expression in vivo protects
the myocardium from dilation and cardiac dysfunction following
pressure overload, and this suppression was accompanied by the
reduction of gp130 signaling.
miR-148a Overexpression Attenuates the Transition of
Pressure-Overload-Induced Concentric toward Eccentric
Remodeling
Our data indicate a correlation between the dynamic miR-148a
expression and the distinct phases of cardiac remodeling under sus-
tained pressure-overload conditions, starting from concentric hyper-
trophy in early phases toward eccentric remodeling in later phases of
overload. To more firmly demonstrate the functional significance of
lowered miR-148a expression in the transition toward eccentric car-
diac hypertrophy, we designed a gene therapeutic approach with
AAV9-148a, where mice were first randomized to receive sham orFigure 4. Cardiac AAV9-miR-148a Overexpression Protects the Heart against E
(A) Design of the study. Two-month-old mice were injected with control AAV9 (AAV9
subjected to sham or TAC surgery. Cardiac geometry and function was determined by s
of miR-148a-3p expression in hearts from mice receiving AAV9-MCS or AAV9-148a vir
four-chamber view (second panel), high-magnification H&E-stained sections (third panel
sections. (D) Measurements of LV mass/BW ratio, (E) LVPWs, (F) LVIDs, (G) EF, (H) fibro
treated mice after sham or TAC surgery. (J) RT-PCR analysis of transcript abundance
AAV9-MCS and AAV9-148a-treated mice after sham or TAC surgery. (K–M) Western
unphosphorylated forms of STAT3 (M) in hearts from mice subjected to sham or TAC s
vector). Data are means ± SEM. One-way ANOVA with Bonferroni’s or Newman-Keul’s
adeno-associated vector serotype 9; TAC, transverse aortic constriction; WGA, wheat g
ventricular posterior wall end systole; LVIDs, left ventricular internal diameter in systole; E
B; Acta1, alpha skeletal actin; Myh7, beta myosin heavy chain. *p < 0.05 versus corres
592 Molecular Therapy Vol. 27 No 3 March 2019TAC surgery for 4 weeks. Next, AAV9 vectors expressing either
mmu-miR-148a (AAV9-148a) or an empty control vector (AAV9-
MCS) were then administered i.v. by injection into the internal jugu-
lar vein of adult mice (Figure 5A) to prevent the observed decrease in
miR-148a in later phases of pressure overload as an approach to
maintain high expression of miR-148a for another 3 weeks. We
confirmed that this approach resulted in higher cardiac miR-148a
expression in sham-operated AAV9-148a-injected mice (Figure 5B),
and these hearts appeared morphologically normalwith no signs of
altered cardiac contractile function, cardiomyocyte hypertrophy,
changes in collagen content, except for a relatively mild induction
of Nppb and Myh7 (Figures 5C–5J).
As expected, at 7 weeks of sustained pressure overload, AAV9-MCS-
injected mice displayed reduced LV wall thickness and increased LV
dilation accompanied with interstitial fibrosis, increased cardiomyo-
cyte size, systolic dysfunction, as well as an induction of the classical
“fetal” gene program (Figures 5C–5J; Tables S5–S7). In contrast, LV
wall thickness was maintained, the extent of LV dilation was attenu-
ated, and systolic contractility was clearly improved in AAV9-148a-
injected mice at 7 weeks of TAC surgery compared to AAV9-MCS
mice receiving TAC surgery (Figures 5C–5G; Table S7). miR-148a
overexpression also resulted in less fibrotic remodeling (Figure 5H)
and a more pronounced induction of “fetal” gene transcripts encod-
ing Nppb and Myh7 (Figure 5J).
Combined, our data reveal that miR-148a expression dynamically
regulates cardiac gp130 expression and alters the responsiveness of
the heart to CT-1 stimulation and downstream STAT3 signaling
strength, where relatively high miR-148a expression produces forms
of concentric hypertrophic remodeling and dampens CT-1 overstim-
ulation that drives deleterious eccentric cardiac remodeling
(Figure 5K).
DISCUSSION
Here, we demonstrate that cardiac expression of miR-148a alters
dynamically in distinct subtypes of human and mouse forms of heart
failure, with highmiR-148a expression in human and mouse forms of
concentric hypertrophy and decreased miR-148a expression in forms
of dilated cardiomyopathy. Mechanistically, miR-148amodulates the
coupling between extracellular CT-1 and cardiac signaling strength ofccentric Hypertrophy, Chamber Dilation, and Systolic Dysfunction
-MCS) or an AAV9 designed to overexpress mmu-miR-148a-3p (AAV9-148a) and
erial Doppler echocardiography at 3 and 6 weeks after surgery. (B) RT-PCR analysis
us. (C) Representative images of whole hearts (top panel), H&E-stained sections of
), Sirius-red-stained sections (fourth panel), andWGA-stained (fifth panel) histological
tic area (Sirius red staining), and (I) cell-surface area in AAV9-CMV- and AAV9-148a-
of hypertrophic stress marker genes Nppa, Nppb, Acta1, and Myh7 in hearts from
blot analysis (K) and quantification of myocardial gp130 (L) or phosphorylated and
urgery and receiving AAV9-148a or AAV9-MCS (MCS, multiple cloning site; empty
multiple-comparison test was used to compare groups. n, number of hearts; AAV9,
erm agglutinin; LV mass/BW, left ventricular mass to body weight ratio; LVPWs, left
F, ejection fraction; Nppa, natriuretic peptide type A; Nppb, natriuretic peptide type
ponding control group; #p < 0.05 versus experimental group.
Figure 5. miR-148a Overexpression Prevents the Transition of Pressure-Overload-Induced Concentric Hypertrophic Remodeling toward Eccentric
Hypertrophy
(A) Design of the study. Two-month-old mice were subjected to sham or TAC surgery and 4 weeks later injected with control AAV9 (AAV9-CMV) or AAV9-148a. Cardiac
geometry and function was determined by serial Doppler echocardiography at 3, 5, and 7weeks after surgery. (B) RT-PCR analysis ofmiR-148a-3p expression in hearts from
mice receiving AAV9-CMV or AAV9-148a virus. (C) Representative images of H&E-stained sections of four-chamber view (top panel), high-magnification H&E-stained
sections (second panel), Sirius-red-stained sections (third panel), and WGA-stained (fourth panel) histological sections. (D) Measurements of LV mass/BW ratio, (E) LVPWs,
(F) LVIDs, (G) EF, (H) fibrotic area (Sirius red staining), and (I) cell surface area in AAV9-CMV and AAV9-148a-treated mice after sham or TAC surgery. (J) RT-PCR analysis of
transcript abundance of hypertrophic stress marker genes Nppa, Nppb, Acta1, and Myh7 in hearts from AAV9-CMV and AAV9-148a-treated mice after sham or TAC
surgery. (K) Model depicting the influence of miR-148a on the CT-1-gp130-STAT3 signaling axis in cardiac stress situations, resulting in differential activation of STAT3
(legend continued on next page)
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Molecular Therapythe canonical STAT3, Akt, Erk5, and Erk1/2 hypertrophic cascades by
targeting gp130, a pivotal co-receptor for cytokines of the IL-6
superfamily.
Using complimentary gain- and loss-of-function studies for miR-
148a in mouse models for cardiac pressure overload, we demonstrate
that the abundance of miR-148a and consequently the reduction of
gp130 levels connect sustained biomechanical forces to diverse forms
myocardial remodeling, with an overall conclusion that miR-148a
expression acts as a protective molecular driver that promotes wall
thickening and concentric remodeling. Here, we used AAVs as a ge-
netic tool to accomplish overexpression of miR-148a. Naturally
occurring viruses have evolved to efficiently transduce their genetic
information into host cells. Recombinant viral vectors are engineered
by replacing non-essential viral genes with foreign genes of therapeu-
tic interest, and used as vehicles for efficient infecting a wide variety of
cell types. AAV vectors are increasingly recognized as reliable tool for
research purposes due to their low immunogenicity, tissue tropism,
and relative safety due to their low rate of genomic integration.29,30
Specifically, AAV vectors of serotype 1/6/9 (AAV1/6/9) that display
varying ranges of cardiac tropism, are used to deliver a variety of ther-
apeutic genes, including small functional non-coding RNAs such as
microRNAs. Future improvement of AAV vectors should address
their limited capacity to carry transgenes of larger sizes. Likewise,
the existence of pre-existing neutralizing antibodies against AAV in
the general population hampers immediate translation of AAV car-
diac gene therapy to clinical stages. Notwithstanding these drawbacks,
AAV vectors can be considered as safe, efficient, and reliable tools for
preclinical cardiac gene therapy applications with high potential as
vectors in clinical trials. Vice versa, lowering of cardiac miR-148a
expression results in increased gp130 expression leading to enhanced
gp130-coupled intracellular signaling, and incites wall thinning and
chamber dilation with the associated increase in stress on the ventric-
ular wall, representing the first irreversible steps toward overt heart
failure in dilated cardiomyopathy. Our findings are proof of the exis-
tence of separable molecular programs primary to concentric hyper-
trophy versus eccentric hypertrophy, chamber narrowing versus
chamber dilation and wall thickening versus wall thinning, all occur-
ring within the venue of biomechanical driven pathways of cardiac
growth and failure.
Cardiac remodeling in patients with heart disease encompass all
quantifiable changes in left ventricular mass and volume, with a
wide variety in the ratio of left ventricular wall thickness to chamber
radius, often referred to as relative wall thickness (RWT) and diag-
nosed by echocardiographic or cardiac MRI data.3 A normal left
ventricular chamber size refers to normal geometry, while differences
in RWT distinguish concentric from normal and from eccentric
remodeling. Concentric hypertrophy tends to arise from pressure-signaling and either concentric or eccentric remodeling. Data are means ± SEM. One-wa
n, number of hearts; AAV9, adeno-associated vector serotype 9; TAC, transverse aortic c
weight ratio; LVPWs, left ventricular posterior wall end systole; LVIDs, left ventricular inter
natriuretic peptide type B; Acta1, alpha skeletal actin;Myh7, beta myosin heavy chain. *
594 Molecular Therapy Vol. 27 No 3 March 2019overload situations in the heart, as observed in patients with aortic
valve stenosis or hypertensive heart diseases, often yielding a substrate
for left ventricular diastolic dysfunction. In contrast, eccentric hyper-
trophy develops secondary to conditions of volume overload of the
myocardium, clinically observed in mitral and aortic regurgitation,
precipitating in a strong reduction of ejection fraction.3 Despite the
existence of a relatively detailed clinical diagnosis and physiological
underpinnings of this spectrum of clinically relevant remodeling
phenotypes, the molecular events that underlie distinct forms of
cardiac hypertrophy still remain poorly charted.31 Accordingly, the
stimulatory circulatory agonists, membrane-bound receptors, and
intracellular signaling cascades that connect biomechanical forces
and the activation of myocardial stress pathways are central to under-
standing the initiation and progression to concentric hypertrophy as
clinically observed in hypertrophic cardiomyopathies versus eccentric
hypertrophy as it occurs in forms of dilated cardiomyopathy.
In cultured cardiomyocytes, CT-1 signals through a gp130 homo-
dimer or gp130/LIFRb heterodimer. Moreover, it was reported to
induce a peculiar form of hypertrophy with increased cardiomyocyte
size, consisting on an increase in cell length but no significant change
in cell width, due to the assembly of sarcomeric units in series, as is
more commonly observed upon stimulation with the canonical
pro-hypertrophic adrenergic agonists or endothelin-1.6,7 The involve-
ment of ERK5 and STAT3 in CT-1-induced longitudinal elongation
has been reported in adult cardiomyocytes7 and it is further sup-
ported by the molecular observation that overexpression of activated
ERK5 induces serial insertion of sarcomeres in neonatal cardiomyo-
cytes in vitro.32 Interestingly, STAT3 upregulates ERK5 in other cell
types. Thus, the possibility that STAT3 mediates the longitudinal
elongation through the downstream activation of ERK5, which deter-
mines cardiomyocyte elongation, requires further investigations.
These morphological differences find a basis in the activation of
distinct signaling cascades and proteomic outcomes between cyto-
kines from the IL-6 superfamily or endothelin-1.33 Elongated cardio-
myocytes, myocardial dilation, and decreased ejection fraction were
also evident following 6 weeks of CT-1 treatment in rats.7 In line,
in the current study we developed and characterized a mouse model
with continuous CT-1 infusion at a clinically relevant concentration
of 20 mg/kg/day, which displayed the hallmarks of eccentric hypertro-
phy after 2 weeks: wall thinning, severe chamber dilation, and a stark
reduction in ejection fraction. The CT-1 infusion rodent models may
prove useful for future studies examining the biochemical, geometric,
or functional ramifications of distinct hypertrophic agonists on the
myocardium.
Genetic studies on the involvement of gp130 in cardiac remodeling
reveal a requirement of gp130-dependent signaling for myocytey ANOVA with Bonferroni’s multiple-comparison test was used to compare groups.
onstriction; WGA, wheat germ agglutinin; LVmass/BW, left ventricular mass to body
nal diameter in systole; EF, ejection fraction;Nppa, natriuretic peptide type A;Nppb,
p < 0.05 versus corresponding control group; #p < 0.05 versus experimental group.
www.moleculartherapy.orgsurvival pathways on the one hand, as well as transmitting prohyper-
trophic signals on the other. Indeed, myocyte-restricted deletion of
gp130 yielded massive apoptotic cell death and rapid onset of dilated
cardiomyopathy following biomechanical stress.20 Heart-restricted
overexpression of a dominant-negative form of gp130 suppressed
many molecular and morphological features of pressure overload-
induced concentric hypertrophic remodeling.21 The molecular
decision between survival and hypertrophy is regulated by the inter-
play between gp130-mediated JAK/STAT activation and suppression
of cytokine signaling 1/3 (SOCS1/3), intrinsic JAK inhibitors, and
negative feedback regulators for gp130 signaling. AAV transfer of
SOCS1 dampened JAK/STAT activation and the transition of
hypertrophy to failure in a pressure-overload model in vivo.34
Moreover, adenovirus-mediated gene transfer of SOCS3 to ventricu-
lar cardiomyocytes completely suppressed both hypertrophic and
antiapoptotic phenotypes in cultured cardiomyocytes induced by
LIF.35 In another study, cardiac-specific SOCS3 knockout mice
showed enhanced activation of the signaling targets STAT3, Akt,
ERK1/2, and p38 MAPK and spontaneous cardiac eccentric remodel-
ing, occurrence of arrhythmias, and signs of heart failure, all in depen-
dence on the presence of gp130, since SOCS3/gp130 double-knockout
mice displayed suppression of the cardiomyopathic phenotype.36
Further downstream of gp130, a variety of signaling branches are
differentially activated by IL-6 cytokines, including the ERK1/2,
p38, and ERK5 MAPK terminal branches, JAK/STAT3, PI3K/Akt,
Gab1/SHP2, and RhoA.11,37,38 In line, Mek5 transgenic mice dis-
played a severe form of eccentric remodeling with wall thinning,
chamber dilation, and severe fibrosis,32 a phenotype that was largely
recapitulated by silencing endogenous miR-148a using an antagomir
strategy in the current study. In contrast, STAT3-deficient mice
spontaneously develop signs of injury, inflammation, and cardiac
dysfunction with advancing age and in response to cardiac stress.
Accordingly, the prevailing message supports a model where IL-6
cytokine-gp130 confers a level of protective signaling in a variety of
cardiac stress conditions and that complete deletion of gp130
signaling components causes widespread cell death. On the other
hand, unrestrained activation of cytokine-gp130 signaling also con-
fers prohypertrophic cues that facilitate the transition to eccentric hy-
pertrophy and systolic dysfunction in situations of biomechanical
stress. This model of cytokine-gp130 signaling is in line with a regu-
latory function of cardiac miR-148a, where higher miR-148a expres-
sion and concomitant reduction of gp130 expression sustains the
protective cell-survival effects while dampening overactivation of
downstream signaling cascades, yielding concentric forms of hyper-
trophy. With sustained periods of biomechanical stress, decreased
miR-148a expression and concomitant derepression of gp130 pro-
motes overactivation of a variety of hypertrophic intracellular signals,
yielding eccentric hypertrophic remodeling, dilated cardiomyopathy,
and systolic dysfunction. As such, the biphasic regulation of miR-
148a provides a mechanistic explanation for the clinically observed
transition from early phase “compensatory” forms of hypertrophy
to later phase decompensation and overt heart failure in the setting
of sustained biomechanical stress.MATERIALS AND METHODS
Human Heart Samples
Approval for studies on human tissue samples was obtained from the
Medical Ethics Committee of the University Medical Center Utrecht,
the Netherlands. All patients or their relatives gave written informed
consent before operation, and procedures were compliant with the
WMA Declaration of Helsinki and the Department of Health and
Human Services Belmont Report. In this study, we included tissue
from the left ventricular free wall of patients undergoing heart trans-
plantation with end-stage heart failure and dilated cardiomyopathy
(DCM) or hypertrophic cardiomyopathy (HCM). Control tissue
was taken from the left ventricular free wall of refused donor hearts
that could not be transplanted for technical reasons and where neither
donor patient histories nor autopsy revealed signs of heart disease
(Table S8).Mouse Models
Mice used in this study were male and female B6CBAF1 wild-type
mice (Charles River Laboratories) of 2–6 months of age. Other
mice used in this study were male calcineurin transgenic mice in a
B6CBAF1 background expressing an activated mutant of calcineurin
in the postnatal heart under control of the 5.5-kb murine Myh6
promoter (Myh6-CnA39). Sample size was determined by a power
calculation based on an echocardiographic effect size. Randomization
of subjects to experimental groups was based on a single sequence of
random assignments. Animal caretakers and investigators were
blinded to group allocation during the experiment and/or when
assessing the outcome. All protocols were performed according to
institutional guidelines and approved by local Animal Care and Use
Committees. All mice were housed on a 12-hr:12-hr light:dark cycle
in a temperature-controlled environment with ad libitum access to
water and chow at Innoser Netherlands BV, a commercial mouse-
breeding company with a quarterly animal health monitoring system
that complies with Federation for Laboratory Animal Science Associ-
ations (FELASA) guidelines and recommendations.Aortic Banding, CT-1 Infusion, and Transthoracic
Echocardiography
TAC or sham surgery was performed in 2-month-old wild-type
B6CBAF1 female and male mice by subjecting the aorta to a defined
27G constriction between the first and second truncus of the aortic
arch, as described previously.26,40 For Doppler echocardiography,
mice were shaved, lightly anaesthetized with isoflurane (mean 1%
in oxygen), and allowed to breathe spontaneously through a nasal
cone. Non-invasive echocardiography was performed as described
previously in detail.24 Doppler was used to calculate the pressure
gradient between the proximal and distal sites of the TAC and only
mice with a pressure gradient >50 mm Hg were included. Chronic
cardiotrophin 1 (20 mg/kg/day dissolved in PBS), isoproterenol
(60 mg/kg/day dissolved in PBS), or saline administration was
performed using Alzet miniosmotic pumps (no. 2002; Alza) surgically
inserted dorsally and subcutaneously (s.c.) in 2-month-old wild-type
B6CBAF1 female and male mice under isoflurane anesthesia and leftMolecular Therapy Vol. 27 No 3 March 2019 595
Molecular Therapyfor an additional 2 weeks. All protocols were performed according to
institutional guidelines and approved by local Animal Care and Use
Committees.
Antagomir Studies
Chemicallymodified antisense oligonucleotides designed to targetmmu-
miR-148a-3p (50-ACAAAGUUCUGUAGUGCAC-30/3CholTEG-30) or
C. elegans miR-39-5p (50-AAGGCAAGCUGACCCUGAAGUU-30/
3CholTEG-30) with a 30 cholesterol conjugation and two phosphoro-
thioate bonds at the very first 50 end and four phosphorothioate bonds
between the last 30 bases41 were synthesized at IntegratedDNATechnol-
ogies (IDT). All antagomirs were high-performance liquid chromatog-
raphy (HPLC) purified and desalted before use. Female and male
wild-type B6CBAF1 mice (8–10 weeks of age) were subjected to sham
or TAC surgery. After 3 days, mice were injected (intraperitoneally)
with antagomir-148a (80 mg kg1 BW) or control antagomir
(80 mg kg1 BW) for 3 consecutive days. Echo analysis was performed
at 3 weeks and 6 weeks after surgery.
AAV Vectors
All of the AAV vectors used in this study were generated by the Inter-
national Centre for Genetic Engineering and Biotechnology (ICGEB)
AAV Vector Unit (AVU) (http://www.icgeb.org/avu-core-facility.
html) using a dual-triple plasmid co-transfection procedure followed
by polyethylene glycol (PEG) precipitation and purification through
CsCl2 gradient centrifugations as described previously.42 Adult
mice were i.v. injected with AAV9-MCS and AAV9-miR-148a via
the jugular vein at a dose of 1  1012 viral genome particles per
animal.
Primary Cardiomyocyte Cultures and Immunocytochemistry
Cardiomyocytes were isolated by enzymatic dissociation of 1- to
2-day-old neonatal rat hearts and processed for immunofluorescence
microscopy as described previously.43 Primary fibroblasts and
endothelial cells were obtained from neonatal rat hearts using endo-
thelial and fibroblast isolation kits (Miltenyi Biotec). Neonatal cardi-
omyocytes were transfected with precursors (Ambion) and inhibitors
(Exiqon) of microRNAs (10 nM) using Oligofectamine (Invitrogen).
For visualization of cardiomyocyte size and sarcomeric organization,
the cells were stained for a2-actinin with mouse monoclonal anti-sar-
comeric a-actinin antibody (Sigma-Aldrich, A7811 clone EA-53,
1:500) followed by rat anti-mouse phenylephrine-Texas red-
conjugated monoclonal antibody (Life Technologies, RM2817 clone
M1/70.15, 1:800). Nuclear staining was performed with
VECTASHIELD Mounting Medium (Vector Laboratories) contain-
ing DAPI. Myocyte hypertrophy was induced by stimulation for
24 hr with phenylephrine (10 mM) as described previously43 or
with CT-1 (2 nM).
Isolation of Adult Mouse Cardiomyocytes, Fibroblasts, and
Endothelial Cells
Cardiomyocytes, fibroblasts, and endothelial cells were isolated from
hearts of B6CBAF1 wild-type mice (2- to 6-months-old) following the
procedure and the buffer preparations of the Langherdorff-free596 Molecular Therapy Vol. 27 No 3 March 2019method previously described.44 In brief, mice were sacrificed via cer-
vical dislocation; the still-beating heart was fully exposed, isolated
from systemic circulation, and perfused once with EDTA buffer
through left ventricular injection. Afterward, the heart was trans-
ferred into a 60-mm dish and perfused again with new EDTA buffer,
moved into a new dish, treated with perfusion buffer, and then serially
perfused with collagenase buffer. The tissue was then pulled gently
into 1-mm3 pieces using forceps and dissociated by pipetting.
Stop buffer was added, cell suspension was passed through a strainer,
and cardiomyocytes were left to settle for 20 min. Fibroblasts and
endothelial cells were separated from the supernatant through
Magnetic-activated cell-sorting method.
pMIR-Reporter Assays
Cos7 cells were purchased at the American Type Culture Collection
(ATCC; CRL-1651) and cultured in DMEM supplemented with
10% fetal bovine serum (FBS), 100 units/mL penicillin-streptomycin
and 2 mmol/L L-glutamine (Thermo Fisher). Cos7 cells were
screened for mycoplasma with the MycoAlert PLUS Mycoplasma
Detection kit (Lonza) upon receipt from ATCC and subsequently
checked on a yearly basis. Cos7 cells were transfected with pMIR
reporter plasmids harboring the entire 30 UTR of mouse gp130,
with pMIR reporter plasmids harboring the first part of the 30 UTR
of mouse gp130, or with pMIR reporter plasmids harboring the latter
section of the gp130 30 UTR using X-tremeGENE 9 (Roche) transfec-
tion reagent, followed by transfection with miR-148a or scrambled
miR precursor molecules using Oligofectamine reagent (Invitrogen).
Luciferase activity was measured 24 hr after transfection with a dual
luciferase assay kit (Promega) using Renilla luciferase as internal con-
trol to correct for transfection efficiency.
Northern Blot Analysis
Northern blotting was performed as described previously24 using
30-digoxigenin-labeled locked nucleic acid oligonucleotides for miR-
148a and U6 small nuclear RNA (Rnu6-2). Detection was achieved
with Fab fragments from polyclonal anti-digoxigenin antibodies,
conjugated to alkaline phosphatase (Roche).
Western Blot Analysis
SDS-PAGE electrophoresis and blotting were performed as described
previously.7 Primary antibodies that were used included anti-gp130
(Cell Signaling Technology; rabbit polyclonal antibody [pAb], cat.
no. 3732), anti-LIFR (Santa Cruz Biotechnology; mouse monoclonal
antibody [mAb], cat sc-515337), anti-CT-1 (Santa Cruz Biotech-
nology; mouse mAb cline AN-B3, cat. no. sc-9991), anti-GAPDH
(Millipore; mouse mAb clone 6C5, cat. no. MAB374), anti-STAT3
(Cell Signaling Technology; mouse mAb clone 124H6, cat. no.
9139), anti-phospho-STAT3 (p-Tyr705) (Cell Signaling Technology;
mouse mAb clone M9C6, cat. no. 4113), anti-Akt (Cell Signaling
Technology; mouse mAb clone 2H10, cat. no. 2967), anti-phospho-
Akt (pSer473) (Cell Signaling Technology; rabbit mAb clone
D7F10, cat. no. 9018), anti-p44/42 MAPK (ERK1/2) (Cell Signaling
Technology; rabbit mAb clone 137F5, cat. no. 4695), anti-phopsho-
p44/42 MAPK (p-Thr202-204-Erk1/2) (Cell Signaling Technology;
www.moleculartherapy.orgrabbit mAb clone D13.14.4E, cat. no. 4370), anti-ERK5 (Cell
Signaling Technology rabbit mAb clone D3I5V, cat. no. 12950),
anti-phospho-ERK5 (p-Thr218/Tyr220) (Cell Signaling Technology;
rabbit pAb, cat. no. 3371) followed by corresponding horseradish
peroxidase (HRP)-conjugated secondary antibodies and enhanced
chemiluminescence (ECL) detection. Western blots were performed
with Stain Free gels for loading control or probed with secondary
antibodies: anti-beta-actin (Sigma-Aldrich; mouse mAb, cat. no.
A1978-100UL) or anti-tubulin (Sigma-Aldrich mouse mAb, cat. no.
T6199-100UL). Signals were detected using the ECL system
(Amersham Pharmacia Biotech). Results are expressed as an n-fold
increase over the values of the control group in densitometric arbi-
trary units.
Real-Time qPCR
Total RNA (1 mg) was used in either miR-based or mRNA-based
reverse transcription. Real-time PCR was performed on a Bio-Rad
iCycler (Bio-Rad) using SYBR Green. Transcript quantities were
compared using the relative Ct method, where the amount of target
normalized to the amount of endogenous control (L7) and relative
to the control sample is given by 2DDCt. For microRNA real-time
PCR, miRNAs were isolated with TRIzol reagent (Invitrogen)
and cDNA was generated with the miScript Reverse Transcription
Kit (QIAGEN). For real-time PCR detection of miRNAs, miScript
Primer Assays and the miScript SYBR Green PCR Kit (QIAGEN)
were used. Regarding the viral genome copy number assay, total
DNAwas extracted and used as substrate of the real-time PCR against
the Cytomegalovirus (CMV) promoter cloned into the AAV vector
genome (primer pair 50-GGACTTTCCTACTTGGCAGT-30 and
50-GTGAGTCAAACCGCTATCCA-30). A standard curve was
obtained by serial dilutions of the AAV plasmid with known concen-
tration. The data were quantified by interpolation with the standard
curve, solving the equation for the linear regression Ct = m (log
quantity) + b.
microRNA Target Prediction
Putative microRNA-148a target genes were identified using the
microRNA databases and target prediction tools miRWalk 2.0
(http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/index.html),
miRBase (https://microrna.sanger.ac.uk/), PicTar (http://pictar.mdc-
berlin.de/), and TargetScan (http://targetscan.org/index.html).
Histological Analysis and (Immunofluorescence) Microscopy
Hearts were arrested in diastole, perfusion fixed with 4% paraformal-
dehyde and PBS solution, embedded in paraffin and sectioned at
4 mm. Paraffin sections were stained with H&E for routine histological
analysis; Sirius red for the detection of fibrillar collagen; and fluores-
cein isothiocyanate (FITC)-labeled wheat-germ-agglutinin (Sigma-
Aldrich, 1:100) to visualize and quantify myocyte cross-sectional
area. Slides were visualized using a Zeiss Axioskop 2Plus with an
AxioCamHRc. Cell surface areas were determined using ImageJ
imaging software (http://rsb.info.nih.gov/ij/). Immune cell stainings
were performed using rat monoclonal anti-CD45 antibody
(Abcam ab23910 IBL-3/16, 1:50) followed by goat anti-rat AlexaFluor 568-conjugated polyclonal antibody (ThermoFisher, A11077,
1:1000), rabbit polyclonal anti-sarcomeric a-actinin antibody
(Abcam, ab137346, 1:100) followed by goat anti-rabbit Alexa Fluor
488-conjugated polyclonal antibody (Thermo Fisher, A11008,
1:1000) and Hoechst 34580 (Thermo Fisher, H21486, 1:1000).
TUNEL stainings were performed on 10-mm paraffin sections as
described previously in detail45,46 using a TMR red TUNEL kit
(Roche). Double staining was performed with anti-phalloidin-FITC
(Sigma,1:500) and/or DAPI (Molecular Probes, 1:500). The samples
were examined with a confocal scanning laser microscope Leica
TCSNT equipped with argon-krypton and helium-neon lasers.
Statistical Analysis
The results are presented as mean ± SEM. Statistical analyses were
performed using Prism software (GraphPad Software), and consisted
of ANOVA followed by Bonferroni’s multiple-comparison test when
group differences were detected at the 5% significance level or Stu-
dent’s t test when comparing two experimental groups. Differences
were considered significant when p < 0.05. For western blot analysis,
normality of distributions was verified by means of the Kolmogorov-
Smirnov test. Data were analyzed using ANOVA followed by a
Newman-Keuls multiple-comparison test when group differences
were detected at the 5% significance level. Differences were consid-
ered significant when p < 0.05.
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